The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Post-transplant maintenance strategies in AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses post-transplant maintenance strategies for patients with acute myeloid leukemia (AML), in particular highlighting recommendations from the Acute Leukemia Working Party on sorafenib for patients with mutant FLT3. Prof. Nagler also discusses preventative therapy with donor lymphocyte infusion (DLI) and the role of gilteritinib post-transplant. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
